Q92837 (FRAT1_HUMAN) Homo sapiens (Human)
Proto-oncogene FRAT1 UniProtKBInterProSTRINGInteractive Modelling
279 aa; Sequence (Fasta)
Available Structures
6 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Glycogen synthase kinase-3 beta (GSK3) complex with FRATtide peptide |
Heteromer P49841; | 2×SO4; | ||||
| Assess | ||||||
| Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors |
Heteromer P49841; | 6×SO4; 3×GOL; 2×ZRL; | ||||
| Assess | ||||||
| GSK3beta complex with N-(6-(3,4-dihydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)acetamide |
Heteromer P49841; | 3×SO4; 1×B4K; | ||||
| Assess | ||||||
| Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors |
Heteromer P49841; | 2×SO4; 2×GOL; 1×ZRK; | ||||
| Assess | ||||||
| Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors |
Heteromer P49841; | 6×SO4; 2×GOL; 2×ZRM; | ||||
| Assess | ||||||
| 5-aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors |
Heteromer P49841; | 3×SO4; 3×GOL; 1×SJJ; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 1gng.1.B | monomer | 0.54 | 100.00 | |||
| Assess | ||||||